'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

Read the whole article on Physorg

More from Physorg